ArticleCase reports in gastrointestinal medicine2026
Visceral Leishmaniasis-Associated Hemophagocytic Lymphohistiocytosis in a Patient With Crohn's Disease in Therapy With Anti-TNFα: A Challenging Diagnostic Case Report.
Article in Case reports in gastrointestinal medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Visceral Leishmaniasis-Associated Hemophagocytic Lymphohistiocytosis in a Patient With Crohn's Disease in Therapy With Anti-TNFα: A Challenging Diagnostic Case Report.Case reports in gastrointestinal medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hemophagocytic lymphohistiocytosis (HLH) is a rare yet life-threatening hyperinflammatory syndrome, increasingly reported in patients with inflammatory bowel disease (IBD) receiving biologic therapy. While Epstein-Barr virus and cytomegalovirus represent the most frequent infectious triggers, visceral leishmaniasis (VL) is extremely uncommon and may be easily ignored outside endemic areas. Case Presentation: We report the case of a 31-year-old man with Crohn's disease treated with escalated anti-TNFα therapy who presented with persistent fever, pancytopenia, hyperferritinemia, hypertriglyceridemia, and progressive systemic inflammation. Both infectious and oncologic workups were initially inconclusive. PET/CT showed splenomegaly, diffuse splenic, and bone marrow hypermetabolism, raising suspicion for a lymphoproliferative disorder; however, bone marrow aspirate revealed systemic inflammation and hemophagocytosis, suggesting HLH and detected intracellular amastigotes consistent with Conclusion: In patients receiving anti-TNF therapy who present with persistent fever, cytopenias, hyperferritinemia, and unexplained systemic inflammation, HLH should be promptly investigated. Early bone marrow examination may facilitate diagnosis by revealing both hemophagocytosis and
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.